|Repros Therapeutics Inc.|
2408 Timberloch Place
United States - Map
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes enclomiphene, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone levels due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
|Repros Therapeutics Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Joseph S. Podolski ,
Chief Exec. Officer, Pres and Director
|Ms. Katherine A. Anderson CPA,
Chief Financial Officer, Chief Accounting Officer and Sec.
|Dr. Jaye L. Thompson Ph.D.,
Sr. VP of Clinical & Regulatory
|Dr. Joachim F. Wernicke M.D., Ph.D.,
Chief Medical Officer
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|